FDA approves Ono’s rare joint tumor drug, setting up battle with Daiichi

The FDA approval of Romvimza in a rare cancer means Ono Pharmaceutical has a fight on its hands. The company must work to displace Daiichi Sankyo’s Turalio, and fortunately, Romvimza appears to have better safety ...